377 related articles for article (PubMed ID: 30181244)
21. Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium.
Chen J; Guanizo A; Luong Q; Jayasekara WSN; Jayasinghe D; Inampudi C; Szczepny A; Garama DJ; Russell PA; Ganju V; Cain JE; Watkins DN; Gough DJ
Oncogene; 2022 Jan; 41(1):138-145. PubMed ID: 34675406
[TBL] [Abstract][Full Text] [Related]
22. TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
Akeno N; Reece AL; Callahan M; Miller AL; Kim RG; He D; Lane A; Moulton JS; Wikenheiser-Brokamp KA
Mol Cancer Ther; 2017 Dec; 16(12):2913-2926. PubMed ID: 28847987
[TBL] [Abstract][Full Text] [Related]
23. Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer.
Wildey G; Shay AM; McColl KS; Yoon S; Shatat MA; Perwez A; Spainhower KB; Kresak AM; Lipka M; Yang M; Behtaj M; Fu P; Alahmadi A; Mneimneh W; Abbas A; Dowlati A
Mol Cancer Ther; 2023 Feb; 22(2):264-273. PubMed ID: 36399634
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
25. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
Peifer M; Fernández-Cuesta L; Sos ML; George J; Seidel D; Kasper LH; Plenker D; Leenders F; Sun R; Zander T; Menon R; Koker M; Dahmen I; Müller C; Di Cerbo V; Schildhaus HU; Altmüller J; Baessmann I; Becker C; de Wilde B; Vandesompele J; Böhm D; Ansén S; Gabler F; Wilkening I; Heynck S; Heuckmann JM; Lu X; Carter SL; Cibulskis K; Banerji S; Getz G; Park KS; Rauh D; Grütter C; Fischer M; Pasqualucci L; Wright G; Wainer Z; Russell P; Petersen I; Chen Y; Stoelben E; Ludwig C; Schnabel P; Hoffmann H; Muley T; Brockmann M; Engel-Riedel W; Muscarella LA; Fazio VM; Groen H; Timens W; Sietsma H; Thunnissen E; Smit E; Heideman DA; Snijders PJ; Cappuzzo F; Ligorio C; Damiani S; Field J; Solberg S; Brustugun OT; Lund-Iversen M; Sänger J; Clement JH; Soltermann A; Moch H; Weder W; Solomon B; Soria JC; Validire P; Besse B; Brambilla E; Brambilla C; Lantuejoul S; Lorimier P; Schneider PM; Hallek M; Pao W; Meyerson M; Sage J; Shendure J; Schneider R; Büttner R; Wolf J; Nürnberg P; Perner S; Heukamp LC; Brindle PK; Haas S; Thomas RK
Nat Genet; 2012 Oct; 44(10):1104-10. PubMed ID: 22941188
[TBL] [Abstract][Full Text] [Related]
26. The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.
Zhang J; Vlasevska S; Wells VA; Nataraj S; Holmes AB; Duval R; Meyer SN; Mo T; Basso K; Brindle PK; Hussein S; Dalla-Favera R; Pasqualucci L
Cancer Discov; 2017 Mar; 7(3):322-337. PubMed ID: 28069569
[TBL] [Abstract][Full Text] [Related]
27. Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth.
Hashwah H; Schmid CA; Kasser S; Bertram K; Stelling A; Manz MG; Müller A
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9701-9706. PubMed ID: 28831000
[TBL] [Abstract][Full Text] [Related]
28. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
[TBL] [Abstract][Full Text] [Related]
29. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Briere D; Sudhakar N; Woods DM; Hallin J; Engstrom LD; Aranda R; Chiang H; Sodré AL; Olson P; Weber JS; Christensen JG
Cancer Immunol Immunother; 2018 Mar; 67(3):381-392. PubMed ID: 29124315
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
[TBL] [Abstract][Full Text] [Related]
31. EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer.
Yang C; Ma S; Zhang J; Han Y; Wan L; Zhou W; Dong X; Yang W; Chen Y; Gao L; Cui W; Jia L; Yang J; Wu C; Wang Q; Wang L
Proc Natl Acad Sci U S A; 2024 Jun; 121(23):e2317790121. PubMed ID: 38814866
[TBL] [Abstract][Full Text] [Related]
32. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.
Pan CH; Chang YF; Lee MS; Wen BC; Ko JC; Liang SK; Liang MC
BMC Cancer; 2016 Nov; 16(1):857. PubMed ID: 27821078
[TBL] [Abstract][Full Text] [Related]
33. MAX Functions as a Tumor Suppressor and Rewires Metabolism in Small Cell Lung Cancer.
Augert A; Mathsyaraja H; Ibrahim AH; Freie B; Geuenich MJ; Cheng PF; Alibeckoff SP; Wu N; Hiatt JB; Basom R; Gazdar A; Sullivan LB; Eisenman RN; MacPherson D
Cancer Cell; 2020 Jul; 38(1):97-114.e7. PubMed ID: 32470392
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive genomic profiles of small cell lung cancer.
George J; Lim JS; Jang SJ; Cun Y; Ozretić L; Kong G; Leenders F; Lu X; Fernández-Cuesta L; Bosco G; Müller C; Dahmen I; Jahchan NS; Park KS; Yang D; Karnezis AN; Vaka D; Torres A; Wang MS; Korbel JO; Menon R; Chun SM; Kim D; Wilkerson M; Hayes N; Engelmann D; Pützer B; Bos M; Michels S; Vlasic I; Seidel D; Pinther B; Schaub P; Becker C; Altmüller J; Yokota J; Kohno T; Iwakawa R; Tsuta K; Noguchi M; Muley T; Hoffmann H; Schnabel PA; Petersen I; Chen Y; Soltermann A; Tischler V; Choi CM; Kim YH; Massion PP; Zou Y; Jovanovic D; Kontic M; Wright GM; Russell PA; Solomon B; Koch I; Lindner M; Muscarella LA; la Torre A; Field JK; Jakopovic M; Knezevic J; Castaños-Vélez E; Roz L; Pastorino U; Brustugun OT; Lund-Iversen M; Thunnissen E; Köhler J; Schuler M; Botling J; Sandelin M; Sanchez-Cespedes M; Salvesen HB; Achter V; Lang U; Bogus M; Schneider PM; Zander T; Ansén S; Hallek M; Wolf J; Vingron M; Yatabe Y; Travis WD; Nürnberg P; Reinhardt C; Perner S; Heukamp L; Büttner R; Haas SA; Brambilla E; Peifer M; Sage J; Thomas RK
Nature; 2015 Aug; 524(7563):47-53. PubMed ID: 26168399
[TBL] [Abstract][Full Text] [Related]
35. Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers.
Mc Leer A; Foll M; Brevet M; Antoine M; Novello S; Mondet J; Cadranel J; Girard N; Giaj Levra M; Demontrond P; Audigier-Valette C; Letouzé E; Lantuéjoul S; Fernandez-Cuesta L; Moro-Sibilot D
Lung Cancer; 2022 May; 167():98-106. PubMed ID: 35183375
[TBL] [Abstract][Full Text] [Related]
36. Trp53 and Rb1 regulate autophagy and ligand-dependent Hedgehog signaling.
Cochrane CR; Vaghjiani V; Szczepny A; Jayasekara WSN; Gonzalez-Rajal A; Kikuchi K; McCaughan GW; Burgess A; Gough DJ; Watkins DN; Cain JE
J Clin Invest; 2020 Aug; 130(8):4006-4018. PubMed ID: 32568216
[TBL] [Abstract][Full Text] [Related]
37. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
38. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
[TBL] [Abstract][Full Text] [Related]
39. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
[TBL] [Abstract][Full Text] [Related]
40. Transformation or tumor heterogeneity: Mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer.
Hao L; Chen H; Wang L; Zhou H; Zhang Z; Han J; Hou J; Zhu Y; Zhang H; Wang Q
Thorac Cancer; 2023 Apr; 14(11):1036-1041. PubMed ID: 36810856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
